View : 21 Download: 0
Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment
- Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment
- Jo, Mun Jeong; Paek, A. Rome; Choi, Ji Seung; Ok, Chang Youp; Jeong, Kyung Chae; Lim, Jae Hyang; Kim, Seok Hyun; You, Hye Jin
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- EUROPEAN JOURNAL OF PHARMACOLOGY
- 0014-2999; 1879-0712
- vol. 769, pp. 257 - 265
- c-Myc; Apoptosis; Caspase-3; Cancer
- ELSEVIER SCIENCE BV
- SCI; SCIE; SCOPUS
- The proto-oncogene c-Myc has been implicated in a variety of cellular processes, such as proliferation, differentiation and apoptosis. Several c-Myc targets have been studied; however, selective regulation of c-Myc is not easy in cancer cells. Herein, we attempt to identify chemical compounds that induce cell death in c-Myc-overexpressing cells (STF-cMyc and STF-Control) by conducting MTS assays on approximately 4000 chemical compounds. One compound, C604, induced cell death in STF-cMyc cells but not STF-Control cells. Apoptotic proteins, including caspase-3 and poly(ADP-ribose) polymerase (PAPP), were cleaved in C604-treated STF-cMyc cells. In addition, 5W620, HCT116 and NCI-H23 cells, which exhibit higher basal levels of c-Myc, underwent apoptotic cell death in response to C604, suggesting a role for C604 as an inducer of apoptosis in cancer cells with c-Myc amplification. C604 induced cell cycle arrest at the G2/M phase in cells, which was not affected by apoptotic inhibitors. Interestingly, C604 induced accumulation of c-Myc and Cdc25A proteins. In summary, a chemical compound was identified that may induce cell death in cancer cells with c-Myc amplification specifically through an apoptotic pathway. (C) 2015 Elsevier B.V. All rights reserved.
- Appears in Collections:
- 의학전문대학원 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.